A new review article in Oncology discusses the potential of multiparametric magnetic resonance imaging (mpMRI) in the diagnosis and management of prostate cancer, and will be useful reading for many advocates and support group leaders.
The article by Gupta et al. (“The state of prostate MRI in 2013“) sets out to place the potential of mpMRI — along with its various components (T2-weighting, diffusion-weighting, dynamic contrast, and magnetic responance specroscopy) — in a highly positive light, so it is important to also read the associated commentaries by Choyte and Turkbey (“The state of prostate MRI in 2013: into the breach“) and by Cornfeld and Sprenkle (“Multiparametric MRI: standardizations needed“) to put things into context.
There is absolutely no doubt that modern mpMRI allows us to do things today that weren’t possible a decade ago. However, overly broad application of this technology in routine clinical practise (as opposed to at selected specialty centers) is a whole different matter and raises questions of cost and the over-application of technology that may benefit only a relatively small proportion of patients is it is not applied with care.